Relmada Therapeutics, Inc, asked for, and was granted, a temporary restraining order and associated injunction against investment bank Laidlaw & Company (UK) Ltd. The temporary restraining order asked that Laidlaw refrain from “continuing to disseminate false and misleading proxy materials.” The U.S. District Court for the District of Nevada issued the order in response to a lawsuit that Relmada filed against their former investment banker. Relmada Therapeutics is a publicly traded specialty pharmaceutical company. The claim was that Laidlaw and its principals disclosed confidential information that it acquired during its time as the company’s investment banker. Relmada claims that Laidlaw has a history of abusing U.S. financial regulations. Relmada succeeded in proving that material lapses and oversights by Laidlaw would cause irreparable harm to the company its stockholders. Relmada also asked for retractions and corrections of said materials.
Laidlaw & Company (UK) Ltd. is a sound company with 170 years of investment banking and wealth management services history. In the United States and the United Kingdom, its services include capital raising, placement of debt and mezzanine capital, and acquisition financing. Matthew Eitner, Chief Executive Officer, and James Ahern, Managing Partner and Head of Capital Markets, focus on the needs of corporate entrepreneurs, institutions, and private clients worldwide. With over 150 employees, Laidlaw is able to develop relationships with and pursue new business. They service their clients on a global basis.
Laidlaw also advises acquisitions, divestitures, financial restructurings, mergers, and strategic alliances. On the wealth management side of their coin, they offer financial planning, portfolio management, and investment advisory services. Laidlaw has a “think outside the box” mentality in their strive to gather assets and distribute financial solutions. Laidlaw provides hands-on management, with a strong retail sales force.